$Damon Inc (DMN.US)$ Damon Motors, a Canadian-based electric motorcycle manufacturer, has expanded its operations into the United States by establishing development offices in San Rafael, California.  This strategic move positions Damon Motors to potentially benefit from various federal and state incentives aimed at promoting electric vehicle (EV) manufacturing and adoption.
Federal Incentives:
The U.S. federal government offers several programs to support EV manufacturers:
Advance...

$Damon Inc (DMN.US)$ Damon Motors, a manufacturer of high-performance electric motorcycles, does not directly control or offer EV grants or incentives.
The U.S. federal government has previously offered tax credits for electric motorcycles under the Qualified Two-Wheeled Plug-In Electric Drive Motor Vehicle Credit. This credit provided up to 10% of the purchase price, capped at $2,500. However, such incentives are subject to change, and their availability can vary from...

$Damon Inc (DMN.US)$ the US government is just announced 13 billion in loans for the evening industry I'll be curious to find out if Damon will be receiving any funding from this pool of money and if so there will be a fantastic to help speed up production this is exciting super bullish!!!!

$Damon Inc (DMN.US)$ Imagine 3000 reserved ordered on an average of $28K. Once production ramps up there will be signifiant costs to get this going. But if into 2 years into production we can see a conservative growth of 15 to 20% growth year over year. That would just be the 2 models available. there is potential in other segments. This could easily be a few billion dollar business. The share price right now is not warranted and I would say that if we are getting close to production as Jay is sa...

$Damon Inc (DMN.US)$ look up Jay Giraud of Damon motors in YouTube. interview about 7 months ago. during covid and post covid the financial state of the markets really change the course of a lot of companies and how they could raise money and how they could deliver their products I could totally empathize with Jay that things have really changed post covid with high interest rates that things became very expensive in Canada and I can attest to this cuz the same has happened ...

$Damon Inc (DMN.US)$ I think people need to be patient with this company they have a lot of potential 100 Mill in backlog is pretty impressive. I think that once they start delivering on this and I know it's been quite a number of years I think into 2025 if they could start delivering on some of these vehicles I'm assuming we're sitting on about 2500 vehicles in backlog I could see this number grow and as well they get involved in the Motorsport world as well so I think th...

$Azitra (AZTR.US)$ Azitra Inc. has received a 'Buy' rating, bolstered by significant progress in its ATR-12 and ATR-04 programs. ATR-12, a genetically modified strain of Staphylococcus epidermidis, is being developed to treat Netherton syndrome, a severe and chronic skin disorder. The company has initiated a Phase 1b clinical trial for ATR-12, marking a crucial step in its development. Additionally, the FDA has granted Fast Track designation to ATR-04, another genetically modified s...

$Azitra (AZTR.US)$  Key updates include a $10 million follow-on offering, the dosing of the first Netherton syndrome patient with ATR-12, an IND clearance and Fast Track designation for ATR-04, and new patent approvals. Upcoming milestones in early 2025 include safety data for ATR-12 and a Phase 1/2 trial for ATR-04 targeting EGFR inhibitor rash. Financially, Azitra reported no revenue for Q3 2024, with increased R&D and G&A expenses totaling $2.9 million, and ...

$Azitra (AZTR.US)$ On November 12, 2024, Azitra, Inc. announced its third-quarter financial results, reporting a net loss of $3.2 million, up from $2.8 million last year, largely due to increased research and development expenses as it progresses with its clinical programs. The company has $5.6 million in cash, supporting its operational runway and ongoing trials. Azitra also noted key advancements, including the start of a Phase 1b trial for ATR-12 for Netherton syndrome and receivi...